Evidence-Based Strategies to Improve Outcomes in Advanced RCC

home / around-the-practice / evidence-based-strategies-to-improve-outcomes-in-advanced-rcc

Experts center their discussion on patient profiles to highlight recent advances in the treatment of renal cell carcinoma and how they apply evidence from research into clinical practice to optimize patient outcomes.

EP. 1: Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

March 28th 2022

Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.

EP. 2: Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

March 28th 2022

Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.

EP. 3: Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 4th 2022

A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.

EP. 4: Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 4th 2022

A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.

EP. 5: Patient Profile 2: Intermediate-Risk RCC Treated With Ipilimumab + Nivolumab

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 11th 2022

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

EP. 6: Discontinuing IO/IO Therapy in Intermediate-Risk Renal Cell Carcinoma

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 11th 2022

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

EP. 7: Optimizing RCC Management: Addressing Quality-of-Life Measures and Metastasis

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 18th 2022

Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.

EP. 8: Novel Combination Strategies in the Treatment of Renal Cell Carcinoma

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 18th 2022

Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.

EP. 9: Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 25th 2022

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

EP. 10: Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

April 25th 2022

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

EP. 11: Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

May 2nd 2022

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

EP. 12: Renal Cell Carcinoma: Future Directions in Care

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

May 2nd 2022

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.